Skip to main content
main-content

23-02-2022 | ASCO GU 2022 | Conference coverage | Video

MAGNITUDE shows benefit of add-on niraparib for mutated mCRPC

share
SHARE

Gerhardt Attard tells us why he is excited about the results of the MAGNITUDE trial evaluating the upfront addition of niraparib to abiraterone acetate in men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations (5:11).

ESMO 2022 congress coverage

Access the latest news and expert insight from the 2022 European Society for Medical Oncology Congress

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.